Adding dapagliflozin to standard liver cancer treatment with metabolic syndrome
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding the diabetes drug dapagliflozin to regular first-line treatment helps people with advanced liver cancer who also have metabolic syndrome. It may improve treatment outcomes for those with these conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced form of liver cancer that cannot be removed with surgery (called unresectable hepatocellular carcinoma)
- You have not had any prior systemic (whole-body) treatment for your liver cancer
- Your first treatment plan includes an immune checkpoint inhibitor (a drug that helps your immune system fight cancer), with or without interventional therapy
- You have metabolic syndrome, meaning you meet at least 3 of these 5: larger waistline (≥90 cm for men, ≥80 cm for women), high triglycerides (≥150 mg/dL or on medication), low HDL cholesterol (<40 mg/dL for men, <50 mg/dL for women or on medication), high blood pressure (≥130/85 mmHg or on medication), or high fasting glucose (≥100 mg/dL or have type 2 diabetes)
- You are between 18 and 75 years old
- You are generally able to perform daily activities (ECOG score 0 or 1)
- Your liver, kidney, and blood cell function are good enough to participate
- You have at least one measurable tumor (as seen on scan)
- You do not have certain other serious medical conditions or have taken SGLT2 inhibitors before
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This trial tests a new drug called ACE723, which is designed to specifically attack liver cancer cells while sparing healthy cells. It is for people with advanced liver cancer that has not responded to or has worsened after standard treatments that included immunotherapy.
This trial tests a combination of medications (a diabetes drug, chemotherapy, targeted therapy, and immunotherapy) as a first treatment for people with advanced liver cancer that cannot be removed by surgery and who also have diabetes. The goal is to see if this combination can help control the cancer while also addressing nerve damage from diabetes.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This trial tests a new treatment approach for liver cancer that has spread or can't be removed. It aims to see if the study drug can help control the cancer.
This trial tests whether adding the drug dapagliflozin (a pill that lowers blood sugar) to standard chemotherapy before breast cancer surgery can improve outcomes. It is for women with high insulin levels and a higher BMI who are about to start chemotherapy.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.